<DOC>
	<DOCNO>NCT01491529</DOCNO>
	<brief_summary>This study ass efficacy safety modify release AFQ056 patient Parkinson 's Disease L-dopa Induced Dyskinesias ( PD-LID )</brief_summary>
	<brief_title>Evaluation Efficacy Safety Modified Release AFQ056 Parkinson 's Patients With L-dopa Induced Dyskinesias</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Males Females 3080 year old Use highly effective method contraception study woman childbearing potential Outpatients Clinical diagnosis Parkinson 's Disease accord UK Parkinson 's Disease Society Brain Bank Clinical Diagnosis criterion Score &gt; /= 2 UPDRS item 32 33 Dyskinesias least 3 month baseline On stable treatment regimen Ldopa antiparkinsonian treatment 4 week prior baseline Demonstrate capacity complete accurate diary rating Patients primary caregiver willing assess condition patient throughout study accordance protocol requirement Group 2 : Patients must stable well tolerate dose amantadine least 4 week prior BL1 must maintain stable dose amantadine remainder study Atypical/secondary form Parkinson 's disease History surgical treatment PD , include deep brain stimulation A score 5 `` ON '' state Modified Hoehn Yahr scale Advanced , severe , unstable disease PD Evidence dementia Treatment certain prohibit medication Amantadine within 2 week prior BL1 visit ( applies Group 1 ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>L-dopa</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Amantadine</keyword>
</DOC>